Century Therapeutics, Inc.

IPSC

US15673T1007

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 28/06/2024 BST			5-day change	1st Jan Change
2.55 ^USD	+0.79%		-10.84%	-23.19%

06-18	Century Therapeutics Proposes Secondary Offering of 7.87 Million Shares	MT
06-17	Piper Sandler Adjusts Price Target on Century Therapeutics to $12 From $9, Maintains Overweight Rating	MT

Century Therapeutics, Inc. cancelled the transaction announced on January 7, 2022

January 06, 2023

On January 7, 2022, Century Therapeutics, Inc. cancelled the transaction.

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	BRISTOL-MYERS SQUIBB COMPANY	41.53 USD	+0.05%	-0.95%	84.19B
	CENTURY THERAPEUTICS, INC.	2.55 USD	+0.79%	-10.84%	215M

Latest news about Century Therapeutics, Inc.

Century Therapeutics Proposes Secondary Offering of 7.87 Million Shares	06-18	MT
Piper Sandler Adjusts Price Target on Century Therapeutics to $12 From $9, Maintains Overweight Rating	06-17	MT
Century Therapeutics Presents Interim Results from Phase 1 Elipse-1 Study At Asco 2024 Annual Meeting	06-03	CI
Century Therapeutics Presents Preclinical Data Highlighting Advances in Ipsc Platform Technology and Programs At 2024 Asgct Annual Meeting	05-10	CI
Century Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Piper Sandler Adjusts Price Target on Century Therapeutics to $9 From $10, Maintains Overweight Rating	04-12	MT
Syncona agrees to sell stake in investee company for GBP7.4 million	04-11	AN
Syncona to Sell Stake in Portfolio Company to Century Therapeutics	04-11	MT
Century Therapeutics Announces Plans to Expand Clinical Development for Its Lead Program, CNTY-101	04-11	CI
Century Therapeutics, Inc. acquired Clade Therapeutics, Inc. from Syncona Limited for $45 million..	04-10	CI
Century Therapeutics, Inc. announced that it expects to receive $59.999982 million in funding from a group of investors	04-10	CI
Century Therapeutics, Inc. agreed to acquire Clade Therapeutics, Inc. from Syncona Limited for $45 million.	04-10	CI
Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research Annual Meeting	04-09	CI
Canaccord Genuity Adjusts Price Target on Century Therapeutics to $24 From $22, Maintains Buy Rating	03-15	MT
Sector Update: Health Care Stocks Retreating Late Afternoon	03-14	MT
Century Therapeutics Shares Fall After Wider Loss, Lower Revenue in 2023	03-14	MT
Century Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-14	CI
Century Therapeutics, Inc. Announces CFO Changes	01-19	CI
Century Therapeutics, Inc.(NasdaqGS:IPSC) dropped from NASDAQ Biotechnology Index	12-15	CI
Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for A Multi-Dosing Strategy for Car iNK Enabled by Allo-Evasion Edits	12-09	CI
Century Therapeutics Gets FDA Clearance for Phase 1 Trial of Potential Systemic Lupus Therapy	12-06	MT
Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus	12-06	CI
Century Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Century Therapeutics, Inc. and FUJIFILM Cellular Dynamics Enter into a Worldwide License Agreement	11-09	CI
Century Therapeutics, Inc. Announces Chief Executive Officer Changes	11-09	CI

Chart Century Therapeutics, Inc.

Duration

Period

More charts

Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with unmet medical need. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Companyâs product candidates include CNTY-101, CNTY-102, CNTY-107, CNTY-104, and CNTY-106. Its CNTY-101 is focused on targeting CD19 for relapsed, refractory B-cell lymphoma. CNTY-102 targets CD19 + CD22 for relapsed, refractory B-cell lymphoma and other B-cell malignancies. CNTY-107 is used of the treatment of solid tumors expressing Nectin-4. CNTY-106 is a multi-specific collaboration program for multiple myeloma.

Sector

Biotechnology & Medical Research

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Century Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.55 USD

Average target price

12.8 USD

Spread / Average Target

+401.96%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CENTURY THERAPEUTICS, INC.	-23.19%	215M
MODERNA, INC.	+19.41%	45.51B
LONZA GROUP AG	+38.65%	39.36B
IQVIA HOLDINGS INC.	-8.62%	38.52B
ALNYLAM PHARMACEUTICALS, INC.	+26.95%	30.74B
CELLTRION, INC.	-13.50%	26.03B
ICON PUBLIC LIMITED COMPANY	+10.74%	25.92B
UNITED THERAPEUTICS CORPORATION	+44.87%	14.13B
MEDPACE HOLDINGS, INC.	+34.36%	12.73B
BIO-TECHNE CORPORATION	-7.14%	11.29B

Other Biotechnology & Medical Research